Antigen-specific therapies in multiple sclerosis

Expert Opinion on Emerging Drugs

Volumn 14, Issue 3, 2009, Pages 551-560

  Giacomini, Paul S ^a   Bar Or, Amit ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antigen specific therapies; BHT 3009; Dirucotide; MS; Recombinant T cell ligands; T cell vaccines

Indexed keywords

ALTERED PEPTIDE LIGAND; BETA INTERFERON; BHT 3009; DNA VACCINE; GLATIRAMER; INACTIVATED VACCINE; LIGAND; MITOXANTRONE; MYELIN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[82-98]; MYELIN REACTIVE T LYMPHOCYTE VACCINE; MYLORAL; NATALIZUMAB; PLACEBO; RECOMBINANT ANTIGEN; RECOMBINANT T CELL LIGAND 1000; T LYMPHOCYTE RECEPTOR VACCINE; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC ENCEPHALOMYELITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; T LYMPHOCYTE;

ANTIGENS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MULTIPLE SCLEROSIS;

EID: 69949145977     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903203790     Document Type: Review

References (54)

1. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008;28(1):29-45 •• A thorough review of the evolving concepts of pathophysiology and immunology of MS.
2. Williams A, Piaton G, Lubetzki C. Astrocytes-friends or foes in multiple sclerosis? Glia 2007;55(13):1300-1312
3. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68(22 Suppl 3):S22-31; discussion S43-54 (Pubitemid 46848608)
4. Bo L, Vedeler CA, Nyland HI, et al. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003;62(7):723-732 (Pubitemid 36870458)
5. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130(Pt 4):1089-1104 (Pubitemid 47355604)
6. Fontoura P, Garren H, Steinman L. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int Rev Immunol 2005;24(5-6):415-446 (Pubitemid 41755155)
7. Vandenbark AA, Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs 2008;22(4):265-273 •• A comprehensive review detailing the appeal and challenges of T-cell vaccine strategies in MS. (Pubitemid 351969834)
8. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 2008;7(11):909-925 • A fine review of novel therapies for MS that are currently under development.
9. Banwell B, Bar-Or A, Cheung R, et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol 2008;63(1):98-111 • An interesting article examining heightened T-cell reactivities in pediatric autoimmune diseases. (Pubitemid 351240556)
10. Lisak RP, Zweiman B, Blanchard N, Rorke LB. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci 1983;62(1-3):281-293 (Pubitemid 14176255)
11. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-1276
12. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA 1994;91(11):4872-4876 (Pubitemid 24177752)
13. Ruggieri M, Avolio C, Livrea P, Trojano M. Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev 2007 Summer;13(2):178-191 (Pubitemid 47052348)
14. Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105(7):967-976
15. Qin Y, Zhang DQ, Prat A, et al. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol 2000;108(1-2):201-206 (Pubitemid 30438768)
16. Saresella M, Marventano I, Longhi R, et al. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J 2008;22(10):3500-3508
17. Hong J, Li N, Zhang X, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005;102(18):6449-6454 (Pubitemid 40617463)
18. Tennakoon DK, Mehta RS, Ortega SB, et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176(11):7119-7129 (Pubitemid 43787894)
19. Jee Y, Piao WH, Liu R, et al. CD4(+) CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 2007;125(1):34-42 (Pubitemid 47374537)
20. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004;172(11):7144-7153 (Pubitemid 38669158)
21. Weber MS, Starck M, Wagenpfeil S, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004;127(Pt 6):1370-1378 (Pubitemid 38745515)
22. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13(8):935-943
23. Kim HJ, Biernacki K, Prat A, et al. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clin Immunol 2004;111(1):38-46 (Pubitemid 38482080)
24. Weiner HL. Current issues in the treatment of human diseases by mucosal tolerance. Ann NY Acad Sci 2004;1029:211-224
25. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259(5099):1321-1324 (Pubitemid 23100270)
26. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363(6425):156-159 (Pubitemid 23147012)
27. Gaur A, Boehme SA, Chalmers D, et al. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J Neuroimmunol 1997;74(1-2):149-158 (Pubitemid 27128990)
28. Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebocontrolled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000;6(10):1176-1182 (Pubitemid 30792199)
29. Kim HJ, Antel JP, Duquette P, et al. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002;104(2):105-114 (Pubitemid 35026220)
30. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6(10):1167-1175 (Pubitemid 30792198)
31. Crowe PD, Qin Y, Conlon PJ, Antel JP. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000;48(5):758-765 (Pubitemid 30823226)
32. Lobell A, Weissert R, Eltayeb S, et al. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J Immunol 1999;163(9):4754-4762 (Pubitemid 29501237)
33. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007;64(10):1407-1415 (Pubitemid 47572664)
34. Garren H, Robinson WH, Krasulova E, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63(5):611-620 • The results of the Phase II MBP DNA vaccine clinical trial.
35. Warren KG, Catz I, Wucherpfennig KW. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci 1997;152(1):31-38 (Pubitemid 27469708)
36. Warren KG, Catz I. Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP(85)VVHFFKNIVTP(96)RT in multiple sclerosis patients. Mult Scler 2000;6(5):300-311
37. Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006;13(8):887-895 (Pubitemid 44124687)
38. Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008;123(1):66-78 • An interesting article exploring trivalent T-cell receptor vaccine mechanisms.
39. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981;292(5818):60-61 (Pubitemid 11048545)
40. Correale J, Lund B, McMillan M, et al. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000;107(2):130-139 (Pubitemid 30347418)
41. Zhang JZ, Rivera VM, Tejada-Simon MV, et al. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol 2002;249(2):212-218 (Pubitemid 34143478)
42. Holoshitz J, Frenkel A, Ben-Nun A, Cohen IR. Autoimmune encephalomyelitis (EAE) mediated or prevented by T lymphocyte lines directed against diverse antigenic determinants of myelin basic protein. Vaccination is determinant specific. J Immunol 1983;131(6):2810-2813 (Pubitemid 14208125)
43. Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand J Immunol 2006;64(3):205-210
44. Zang YC, Hong J, Tejada-Simon MV, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol 2000;30(3):908-913 (Pubitemid 30216265)
45. Loftus B, Newsom B, Montgomery M, et al. Autologous attenuated T-cell vaccine (Tovaxin (R)) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Clin Immunol 2009;131(2):202-215 • The most recent data evaluating the autologous attenuated T-cell vaccine in MS.
46. Offner H, Sinha S, Wang C, et al. Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Rev Neurosci 2008;19(4-5):327-339 •• A comprehensive review focusing on recombinant T-cell ligands.
47. Wang C, Mooney JL, Meza-Romero R, et al. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol 2003;171(4):1934-1940 (Pubitemid 36966477)
48. Sinha S, Subramanian S, Proctor TM, et al. A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J Neurosci 2007;27(46):12531-12539 (Pubitemid 350127826)
49. Wang C, Gold BG, Kaler LJ, et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 2006;98(6):1817-1827 (Pubitemid 44313640)
50. Freedman MS. Bone marrow transplantation: does it stop MS progression? J Neurol Sci 2007;259(1-2):85-89
51. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008;7(7):626-636
52. Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006;66(12):1935-1937 (Pubitemid 44049833)
53. Inglese M, Mancardi GL, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004;75(4):643-644 (Pubitemid 38406670)
54. Metz I, Lucchinetti CF, Openshaw H, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007;130(Pt 5):1254-1262 (Pubitemid 47355940)